Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (321)	2/27/2003 10:58:13 AM
From: Jibacoa	Respond to of 3722

SGEN One of the two Biotech Cos. in Bill's Portfolio <g> is up 8.10% on volume of 17K almost half of its daily volume. biz.yahoo.com It announced last week that Paul J. Carter, Ph.D.joined the company as Senior Director, Antibody Technologies. He had held positions at DNA, IMNX & AMGN. (While at DNA he played a role in development of Herceptin.) biz.yahoo.com Insiders hold 70% of the shares (albeit have reportedly done some selling<g>) but the institutions that hold more than 110% of the float had done some buying <g> SGEN reportedly has about $0.85 cash/share and has been trading around 1.9 of book.The float is less than 10M The stock opened on an up-gap which already has been closed.<g> It needs to close above the 3.25 level siliconinvestor.com Bernard